Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Benitec Biopharma Inc. is a clinical-stage biotechnology company specializing in genetic medicines for treating serious genetic disorders. Its proprietary DNA-directed RNA interference (ddRNAi) platform combines RNA interference with gene therapy to achieve sustained silencing of disease-causing genes and simultaneous replacement with functional wildtype genes. The company’s lead product candidate, BB-301, targets Oculopharyngeal Muscular Dystrophy (OPMD) using this “silence and replace" approach, aiming for durable therapeutic effects after a single administration.
This description was generated via AI from an annual report. Updated about 1 year ago.